ЗАПОР (СООБЩЕНИЕ 2: ЛЕЧЕНИЕ) (обзор литературы)
https://doi.org/10.51523/2708-6011.2014-11-2-4
Аннотация
В статье рассмотрены вопросы выбора метода лечения запора с позиций «доказательной медицины», учитывая индивидуальные особенности заболевания у конкретного пациента. Приведены сведения о наиболее эффективных и безопасных лекарственных средствах для терапии запоров, а также показания к методу биологической обратной связи (biofeedback) и хирургическому лечению.
Об авторах
Э. Н. Платошкин
Гомельский государственный медицинский университет
Беларусь
Беларусь
С. А. Шут
Гомельский государственный медицинский университет
Беларусь
Беларусь
Список литературы
1. Буторова, Л. И. Запор: диагностика и основные принципы назначения слабительных средств / Л. И. Буторова // Клин. перспективы гастроэнтерологии, гепатологии. - 2003. - № 4. - С. 19-25.
2. Tack, J. Treatment of chronic constipation: current pharmacologic approaches and future directions / J. Tack, S. Müller-Lissner // Clin. Gastroenterol. Hepatol. - 2009. - Vol. 7. - P. 502-508.
3. World Gastroenterology Organisation Global Guidelines. Constipation: a global perspective. November 2010. [Electronic resourse] Mode of access: http://www.worldgastroenterology.org/constipation.html. - Date of accessed 20 January 2013.
4. Шептуллин, А. А. Новые возможности лекарственной терапии хронических запоров [Electronic resourse] / ed. А. А. Шептуллин. - Mode of access: http://www. internist.ru/articles/ gastroenterology/ gastroenterology_414.html. - Date of accessed: 05 February 2014.
5. Sanger, G. J. Constipation, IBS and the 5-HT4 receptor: what role for prucalopride? / G. J. Sanger, E. M. M. Quigley // Clin Med Insights: Gastroenterology. - 2010. - № 3. - Р. 21-33.
6. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder / E. P. Bouras [et al.] // Gastroenterology. - 2001. - № 120. - P. 354-360.
7. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation / C. E. Sloots [et al.] // Aliment Pharmacol Ther. - 2002. - Vol. 16. - P. 759-767.
8. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers / A. C. Poen [et al.] // Aliment Pharmacol Ther. - 1999. - Vol. 13. - P. 1493-1497.
9. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers / A. V. Emmanuel [et al.] // Gut. - 1998. - Vol. 42. - P. 511-516.
10. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study / M. Camilleri, [et al.] // Neurogastroenterol Motil. - 2009. - Vol. 21. - P. 1256-1317.
11. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation / J. F. Johanson [et al.] // Aliment Pharmacol Ther. - 2008a. - Vol. 27. - P. 685-696.
12. Метод биологической обратной связи (biofeedback) [Electronic resourse] / Mode of access: www.airmed.com.ua. Date of accessed 11 February 2014.
13. Рекомендации по диагностике и лечению хронического запора: Методическое пособие / В. Т. Ивашкин [и др.]. - М.: ООО «НПЦ Мединформ», 2014. - 6 с.
14. Diagnosis and treatment of chronic constipation - a European perspective / J. Tack [et al.] // Neurogastroenterol Motil. - 2011. - Vol. 23. - P. 697-710.
15. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride / G. E. Boeckxstaens [et al.] // Am J Gastroenterol. - 2002. - Vol. 97. - P. 194-197.
16. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans / E. P. Bouras [et al.] // Gut. - 1999. - Vol. 44. - P. 682-686.
17. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials [abstract] / M. Boyce [et al.] // Gastroenterology. - 2009. - Vol. 136. (Suppl. 1). - T. 1265.
18. An evidence-based systematic review of the management of irritable bowel syndrome / L. J. Brandt [et al.] // Am J Gastroenterol. - 2009. - Vol. 104. - P. 1-35.
19. Evidence-based position statement on the management of chronic constipation in North America / L. J. Brandt [et al.] // Am J Gastroenterol. - 2005. - Vol. 100 (Suppl. 1). - P. 5-21.
20. A placebo-controlled trial of prucalopride for severe chronic constipation / M. Camilleri [et al.] // N Engl J Med. - 2008b. - Vol. 358. - P. 2344-2354.
21. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies / M. Camilleri [et al.] // Aliment Pharmacol Ther. - 2010. - Vol. 32. - P. 1113-1123.
22. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries / K. Y. Chan [et al.] // Eur J Pharmacol. - 2009. - Vol. 619. - P. 61-67.
23. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial / G. Coremans [et al.] // Digestion. - 2003. - Vol. 67. - P. 82-89.
24. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers / A. M. De Schryver [et al.] // Aliment Pharmacol Ther 2002. - Vol. 16. - P. 603-612.
25. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation / J. A. Di Palma [et al.] // Am J Gastroenterol. - 2007. - Vol. 102. - P. 1964-1971.
26. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies / D. A. Drossman [et al.] // Aliment Pharmacol. Ther. - 2009. - Vol. 29. - P. 329-341.
27. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation / D. Dubois [et al.] // Neurogastroenterol Motil. - 2010. - Vol. 22. - P. 54-63.
28. Pharmacological management of constipation / A. V. Emmanuel [et al.] // Neurogastroenterol. Motil. - 2009. - Vol. 21, (Suppl. 2). - P. 41-54.
29. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locallyacting type-2 chloride channel activator, in patients with chronic constipation / J. F. Johanson[et al.] // Am J Gastroenterol. - 2008b. - Vol. 103. - P. 170-177.
30. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation / J. M. Johnston [et al.] // Gastroenterology. - 2010. - Vol. 139. - P. 1877-1886.
31. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury / K. Krogh [et al.] // Scand J Gastroenterol. - 2002. - Vol. 37. - P. 431-436.
32. Efficacy of linaclotide for patients with chronic constipation / A. J. Lembo [et al.] // Gastroenterology. - 2010. - Vol. 138. - P. 886-895.
33. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation / S. Müller-Lissner [et al.] // Neurogastroenterol Motil. - 2010. - Vol. 22. - P. 991-998.
34. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel / F. Potet [et al.] // J Pharmacol Exp Ther. - 2001. - Vol. 299. - P. 1007-1012.
35. Quigley, E. M. M. Cisapride. What can we learn from the rise and fall of a prokinetic? / E. M. M. Quigley // J Dig Dis. - 2011. - Vol. 12. - P. 147-156.
36. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study / E. M. Quigley [et al.] // Aliment Pharmacol Ther. - 2009. - Vol. 29. - P. 315-328.
37. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives / J. Tack [et al.] // Gut. - 2009. - Vol. 58. - P. 357-365.
Рецензия
Для цитирования:
Платошкин Э.Н., Шут С.А. ЗАПОР (СООБЩЕНИЕ 2: ЛЕЧЕНИЕ) (обзор литературы). Проблемы здоровья и экологии. 2014;(2):21-25. https://doi.org/10.51523/2708-6011.2014-11-2-4
For citation:
Platoshkin E.N., Shut S.A. CONSTIPATION (REPORT 2: TREATMENT) (literature review). Health and Ecology Issues. 2014;(2):21-25. (In Russ.) https://doi.org/10.51523/2708-6011.2014-11-2-4
Просмотров: 262
Послать статью по эл. почте 